Promising cocktail of drugs takes on rare blood cancer
NCT ID NCT07168317
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing a combination of five drugs—tislelizumab, cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone—in 40 people newly diagnosed with angioimmunoblastic T-cell lymphoma (AITL), a rare and aggressive blood cancer. The goal is to see if this mix can shrink tumors and help patients live longer without the cancer coming back. Researchers hope the combination will be more effective than current treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tislelizumab, cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone
- What this could lead to
- If successful, this combination could offer a more effective first-line treatment for a rare and aggressive lymphoma, potentially improving response rates and long-term survival.
- What could go wrong
- This is a small, early-phase (phase 2) study with no control group, so results may not be definitive. The drug combination also carries risks of serious side effects like infections and organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEW DIAGNOSED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Affiliated Hospital of Xuzhou Medical University
RECRUITINGXuzhou, Jiangsu, 221000, China